USPTO Examiner DONOHUE SEAN R - Art Unit 1618

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19268785INJECTABLE LEUCOVORIN FORMULATIONS AND METHODS OF PREPARING SAMEJuly 2025January 2026Allow611YesNo
19002144NEUROPEPTIDE Y1 RECEPTOR (NPY1R) TARGETED THERAPEUTICS AND USES THEREOFDecember 2024February 2026Allow1421YesNo
18948808DUAL MODE RADIOTRACER AND-THERAPEUTICSNovember 2024September 2025Allow1020NoNo
18947606RADIOPHARMACEUTICALSNovember 2024July 2025Allow820YesNo
18931596RADIOPHARMACEUTICALS INCLUDING ENCAPSULATED GA+99mTcOctober 2024November 2025Allow1321NoNo
18805445CARBONIC ANHYDRASE IX-TARGETING RADIOACTIVE DIAGNOSTIC AND THERAPEUTIC MEDICAMENT AND METHOD FOR PREPARING SAMEAugust 2024October 2025Allow1530NoNo
18791270[177LU] LUTETIUM-PSMA I&T COMPOSITION AND DOSIMETRY, KIT, METHOD OF MAKING, AND METHOD OF USING THEREOFJuly 2024April 2025Allow920YesNo
18771562Structural Optimization Method to Improve the Theranostic Performance of Peptide Receptor-Targeted Radionuclide Therapy for CancersJuly 2024April 2025Allow920YesNo
18670587RADIOLABELED CANNABINOID RECEPTOR 2 LIGANDMay 2024January 2026Allow1910NoNo
18646785RADIONUCLIDE LABELED POLYPEPTIDE CONJUGATES AND USES THEREOFApril 2024March 2025Allow1121NoNo
18640620COMBINATIONS OF IMAGING AGENT CONJUGATES AND APPLICATION THEREOFApril 2024March 2026Allow2331NoNo
18640169ZWITTERIONIC METAL CHELATORSApril 2024June 2025Allow1421YesNo
18597037METHOD OF TREATMENT OF NEUROENDOCRINE TUMORSMarch 2024February 2026Abandon2310NoNo
18587915NANO-PARTICLES OF MENAQUINONE-9 AND METHODS OF TREATMENTFebruary 2024July 2025Allow1620YesYes
18432631FLUORINE-18 LABELED COMPOSITIONS AND THEIR USE IN IMAGING OF BIOLOGICAL TISSUEFebruary 2024December 2025Abandon2210NoNo
18419562POSITRON EMISSION TOMOGRAPHY RADIOTRACER FOR DISEASES ASSOCIATED WITH TRANSLOCATOR PROTEIN OVEREXPRESSION, TRANSLOCATOR PROTEIN-TARGETING LIGAND FOR FLUORESCENCE IMAGING-GUIDED SURGERY AND PHOTODYNAMIC THERAPY, AND PRODUCTION METHODS THEREFORJanuary 2024August 2025Allow1810NoNo
18401983ELECTROSPUN BIOCOMPATIBLE FIBER COMPOSITIONSJanuary 2024January 2026Abandon2520NoNo
18402399HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEINJanuary 2024October 2025Allow2131YesNo
18390906HDAC6 Inhibitors and Imaging AgentsDecember 2023July 2025Allow1920NoNo
18526575RADIOLABELLED MGL PET LIGANDSDecember 2023April 2025Allow1610NoNo
18513283MANNOSE DERIVATIVE AND APPLICATION THEREOFNovember 2023July 2024Allow820NoNo
18505688COMPLEX COMPRISING A PSMA-TARGETING COMPOUND LINKED TO A LEAD OR THORIUM RADIONUCLIDENovember 2023March 2025Allow1610YesNo
18289027PEPTIDE LIGAND TARGETING CARBONIC ANHYDRASE IX, PEPTIDE CONSTRUCT COMPRISING SAME, AND USES THEREOFOctober 2023January 2025Allow1401NoNo
18380822METHOD OF USING ADENOSINE AND DIPYRIDAMOLE FOR PHARMACOLOGIC STRESS TESTING, WITH SPECIFIC COMPOSITIONS, UNIT DOSAGE FORMS AND KITSOctober 2023June 2025Abandon2010NoNo
18477509HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFSeptember 2023November 2025Allow2620YesYes
18477496HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOFSeptember 2023October 2025Allow2520YesYes
18456931PSMA TARGETED COMPOUNDS AND USES THEREOFAugust 2023April 2024Allow720YesNo
18452312CONJUGATES AND THEIR USE AS IMAGING AGENTSAugust 2023January 2025Allow1730YesNo
18229588HETEROARYL COMPOUNDS AND USES THEREOFAugust 2023September 2025Abandon2620NoNo
18349201METHOD FOR PRODUCING Ac-225 SOLUTION AND METHOD FOR PRODUCING MEDICINE USING Ac-225 SOLUTIONJuly 2023April 2025Abandon2110NoNo
18209798PSMA TARGETED RADIOHALOGENATED UREAS FOR CANCER RADIOTHERAPYJune 2023September 2025Abandon2820NoNo
18207628CONJUGATES DERIVED FROM NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND METHODS OF USE THEREOF IN IMAGINGJune 2023March 2025Abandon2210NoNo
18201806F-18 LABELED CHIRAL PURE DERIVATIVE OF HYDROXYFURAN, PREPARATION METHOD AND USE THEREOFMay 2023August 2024Allow1530NoNo
18200950COMPOUNDS FOR TAU PROTEIN DEGRADATIONMay 2023December 2025Allow3030NoNo
18317224ASTATINE SOLUTION AND METHOD FOR PRODUCING SAMEMay 2023July 2025Allow2620NoNo
18144547COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN THE BRAINMay 2023September 2024Allow1610NoNo
18310588Semifluorocarbon Compound Containing Contrast AgentMay 2023February 2025Abandon2210NoNo
18251217OLIGONUCLEOTIDE-BASED THERAPEUTICS AND USES THEREOFApril 2023July 2025Abandon2731YesNo
18305702One-Step Labeling of Antibodies to High Specific Activity with Actinium-225April 2023June 2024Abandon1410NoNo
18135595RADIOPHARMACEUTICAL AND METHODSApril 2023October 2025Allow3020YesYes
1814998118F-LABELED PSMA-TARGETED PET IMAGING AGENTSJanuary 2023September 2025Abandon3331YesNo
18086075CASSETTE FOR STABILISED RADIOLABELLING REACTIONDecember 2022July 2024Abandon1920NoNo
18061715RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDSDecember 2022July 2024Abandon1920NoNo
17962686ELUENT SOLUTIONOctober 2022June 2025Abandon3220YesNo
17956326F-18 POSITRON DIAGNOSTIC CONTRAST AGENT PRECURSOR AND METHOD OF MANUFACTURING THE SAMESeptember 2022September 2025Allow3601NoNo
17882708PHARMACEUTICAL COMPOSITION CONTAINING 211AT-LABELED AMINO ACID DERIVATIVE, AND METHOD FOR PRODUCING SAID PHARMACEUTICAL COMPOSITIONAugust 2022November 2025Abandon3940YesNo
17879351MULTIMODAL PET/MRI CONTRAST AGENT AND A PROCESS FOR THE SYNTHESIS THEREOFAugust 2022April 2025Abandon3220NoNo
17795792STRUCTURAL OPTIMIZATION METHOD TO IMPROVE THE THERANOSTIC PERFORMANCE OF PEPTIDE RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR CANCERSJuly 2022August 2025Allow3720NoNo
17759336METHOD FOR THE PREPARATION OF N-MONOFLUOROALKYL TROPANES AND THEIR USEJuly 2022October 2025Allow3910NoNo
17870973Method, Apparatus, and System for Radiation TherapyJuly 2022September 2024Abandon2510NoNo
17869104METHOD FOR PRODUCING Ac-225 SOLUTION AND METHOD FOR PRODUCING MEDICINE USING Ac-225 SOLUTIONJuly 2022May 2023Allow1020NoNo
17793091FATTY ACID DERIVATIVE LABELED WITH POSITRON-EMITTING RADIONUCLIDEJuly 2022January 2026Abandon4210NoNo
17810370FAP INHIBITORJuly 2022January 2025Abandon3030NoNo
17854532177-LU LABELED ACTIVE SITE INHIBITED FACTOR VIIJune 2022November 2025Allow4020YesYes
17850056RADIOPHARMACEUTICAL PRODUCTSJune 2022June 2025Abandon3520NoNo
17849297DUAL MODE RADIOTRACER AND -THERAPEUTICSJune 2022April 2025Allow3440NoYes
17846690METHODS OF CANCER DETECTION USING PARPI-FLJune 2022January 2026Abandon4340NoNo
17836994Metal Tricarbonyl Complexes Comprising Substituted Iminodiactic Acid Ligands and Uses as Radioisotope TracersJune 2022January 2025Abandon3120NoNo
17757017RADIOMICS-BASED TREATMENT DECISION SUPPORT FOR LUNG CANCERJune 2022June 2025Allow3710NoNo
17831698RADIOPHARMACEUTICAL COMPOSITIONS OF RADIOACTIVE HALOGENATED BENZYLGUANIDINEJune 2022February 2025Abandon3340NoNo
17745100LABELING PRECURSORS WITH SQUARIC ACID COUPLINGMay 2022June 2023Allow1311NoNo
17776330RADIOHALOGEN PROSTHETIC MOIETIES AND RADIOLABELED BIOMOLECULESMay 2022January 2026Allow4411NoNo
17775150RADIOLABELLED TARGETING LIGANDSMay 2022November 2025Abandon4210NoNo
17729881DEUTERATED COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEINApril 2022December 2025Allow4420YesNo
17722628RADIOLIGANDS FOR IMAGING THE ID01 ENZYMEApril 2022May 2025Abandon3720NoYes
17715661ISOINDOLINONE COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEINApril 2022February 2026Allow4620NoNo
17695252SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORSMarch 2022May 2024Abandon2620NoNo
17642179PSMA BINDER AND USE THEREOFMarch 2022June 2025Allow4040NoNo
17592684SYSTEM AND METHOD FOR QUANTITATIVE MAPPING OF MITOCHONDRIAL COMPLEX 1February 2022January 2024Abandon2320NoNo
17649930METHOD AND DEVICE FOR DIRECT PRODUCTION OF RADIO-ISOTOPE BASED CANCER TREATMENT PHARMACEUTICALSFebruary 2022May 2024Allow2730YesNo
17574838ELECTROSPUN BIOCOMPATIBLE FIBER COMPOSITIONSJanuary 2022May 2024Abandon2820NoNo
17557755ELUENT SOLUTIONDecember 2021June 2024Abandon2920NoNo
17619791COMPOUNDS FOR FAST AND EFFICIENT CLICK RELEASEDecember 2021January 2026Allow4921YesYes
17534711Imaging AgentsNovember 2021June 2024Abandon3120YesNo
17455170HDAC6 Inhibitors and Imaging AgentsNovember 2021September 2023Allow2210NoNo
17522144MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOFNovember 2021December 2023Abandon2521NoNo
17594325CONJUGATES AND THEIR USE AS IMAGING AGENTSOctober 2021October 2024Abandon3610NoNo
17486875RADIOPHARMACEUTICAL AND METHODSSeptember 2021May 2023Abandon2030YesNo
17477479NOVEL COMPOUNDS FOR IMAGING TAU PROTEINS THAT ACCUMULATE IN BRAINSeptember 2021February 2023Allow1721YesNo
17477411HETEROARYL COMPOUNDS AND USES THEREOFSeptember 2021October 2023Abandon2541YesNo
17439536RIGIDIFIED PENTADENTATE CHELATING AGENTS USEFUL FOR THE [AL18F]2+ LABELLING OF BIOMOLECULESSeptember 2021April 2025Allow4320NoNo
17474916COMPLEX POLYSACCHARIDE-BOUND RADIOISOTOPE CHELATES AND METHODS OF TREATING MALIGNANCIES THEREWITHSeptember 2021June 2022Abandon910NoNo
17436162[18F]-Labeled Benzothiazole Derivative As PET RadiotracerSeptember 2021June 2025Abandon4520NoNo
17433309USE OF ECHOGENIC COATING FOR ULTRASOUND IMAGING OF MEDICAL DEVICES IN DEEP TISSUE LAYERSAugust 2021March 2026Abandon5440YesNo
17310758COMBINATION OF PD-1/PD-L1 INHIBITORS AND TARGETED THORIUM CONJUGATESAugust 2021January 2025Abandon4110NoNo
17395319METAL COMPLEXES AND FLUORINATION THEREOFAugust 2021May 2025Abandon4540NoNo
17395055HETEROBIARYL COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEINAugust 2021March 2024Allow3131YesNo
1739028418F-LABELED TRIAZOLE CONTAINING PSMA INHIBITORSJuly 2021March 2026Allow5640NoYes
17372410RADIOLABELLED AND NONRADIOLABELLED PEGYLATED COMPOUNDS AND USES THEREOFJuly 2021February 2024Abandon3220NoNo
17366681NOVEL FORMULATION AND METHOD OF SYNTHESISJuly 2021April 2024Abandon3420NoNo
17356757PRECURSOR COMPOUND OF RADIOACTIVE HALOGEN-LABELED ORGANIC COMPOUNDJune 2021February 2024Abandon3220NoNo
17353611PROBES FOR IMAGING HUNTINGTIN PROTEINJune 2021March 2024Allow3231YesNo
17353627PROBES FOR IMAGING HUNTINGTIN PROTEINJune 2021August 2023Allow2621NoNo
17344739COMPOSITIONS AND METHODS FOR MEASURING OXIDATIVE STRESSJune 2021October 2025Allow5360YesNo
17344582HETEROCYCLIC COMPOUNDS AND IMAGING AGENTS FOR IMAGING HUNTINGTIN PROTEINJune 2021September 2023Allow2831YesNo
17317133HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOFMay 2021January 2025Allow4530NoYes
17317529COMPOSITION AND METHODS FOR TUMOR IMAGING AND TREATMENTMay 2021July 2024Allow3820YesYes
17314158PURIFICATION METHOD AND COMPOSITIONSMay 2021February 2025Abandon4540YesNo
17314366METHODS AND MATERIALS FOR MAKING PET RADIOTRACERSMay 2021November 2025Abandon5420NoYes
17246184TAU PET IMAGING LIGANDSApril 2021September 2023Abandon2820NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DONOHUE, SEAN R.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
46
Examiner Affirmed
26
(56.5%)
Examiner Reversed
20
(43.5%)
Reversal Percentile
66.4%
Higher than average

What This Means

With a 43.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
124
Allowed After Appeal Filing
33
(26.6%)
Not Allowed After Appeal Filing
91
(73.4%)
Filing Benefit Percentile
38.6%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 26.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner DONOHUE, SEAN R - Prosecution Strategy Guide

Executive Summary

Examiner DONOHUE, SEAN R works in Art Unit 1618 and has examined 678 patent applications in our dataset. With an allowance rate of 40.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 37 months.

Allowance Patterns

Examiner DONOHUE, SEAN R's allowance rate of 40.4% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by DONOHUE, SEAN R receive 2.67 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by DONOHUE, SEAN R is 37 months. This places the examiner in the 31% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +20.6% benefit to allowance rate for applications examined by DONOHUE, SEAN R. This interview benefit is in the 64% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 11.9% of applications are subsequently allowed. This success rate is in the 7% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 27.0% of cases where such amendments are filed. This entry rate is in the 38% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 27.6% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 30% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 53.5% of appeals filed. This is in the 24% percentile among all examiners. Of these withdrawals, 41.5% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.

Petition Practice

When applicants file petitions regarding this examiner's actions, 85.8% are granted (fully or in part). This grant rate is in the 87% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 51% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Expect multiple rounds of prosecution: This examiner issues more office actions than average. Address potential issues proactively in your initial response and consider requesting an interview early in prosecution.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.